Clinical Studies – gabarx.com https://www.gabarx.com Wed, 31 Jul 2024 21:40:11 +0000 en-US hourly 1 https://www.gabarx.com/wp-content/uploads/2024/11/cropped-GABA-LaOGO-32x32.png Clinical Studies – gabarx.com https://www.gabarx.com 32 32 169575290 GRX-917 is a Potent Inhibitor of the NLRP3/IL-1 Beta Inflammation Pathway https://www.gabarx.com/2024/04/29/grx-917-is-a-potent-inhibitor-of-the-nlrp3-il-1-beta-inflammation-pathway/ https://www.gabarx.com/2024/04/29/grx-917-is-a-potent-inhibitor-of-the-nlrp3-il-1-beta-inflammation-pathway/#respond Mon, 29 Apr 2024 22:15:39 +0000 https://gabarx.com/?p=2664 Etifoxine (and therefore GRX-917) was recently shown to reduce neuroinflammation via inhibition of the NLRP3 inflammasome pathway (https://www.biorxiv.org/content/10.1101/2023.09.19.558428v1). Etifoxine inhibits the NLRP3 inflammasome pathway broadly, as shown by marked reductions of NLRP3, IL-1beta, and TNF. In addition, significant improvement in clinical scores were observed in the mouse EAE model of acute inflammation, confirming prior studies with etifoxine. NLRP3 inflammasome pathway inhibition thus appears to underlie etifoxine’s efficacy in animal models of neuroinflammation and neurodegeneration, including multiple sclerosis, Alzheimer’s Disease, Parkinson’s Disease, stroke, head trauma, pain, and neuropathy.

GABA Therapeutics’ lead clinical asset, GRX-917 (deuterated-etifoxine), exhibits equivalent pharmacology, MOA, safety, and efficacy. This new mechanistic insight not only supports assessment of GRX-917 for neuroinflammatory disorders, but also points to GRX-917’s potential for the treatment of peripheral NLRP3 inflammatory pathway disorders, such as inflammatory bowel disease, osteoarthritis, rheumatoid arthritis, lupus, asthma, gout, NASH, chronic kidney disease, and others. anxiety NLRP3 neuroinflammation neurodegeneration IBD multiplesclerosis neuropathy

For questions contact:
Richard G. Farrell
Chief Financial Officer

Follow us on LinkedIn

We post current progress and developments on our GABA Therapeutics’ LinkedIn page. Click here to follow us LinkedIn.

]]> https://www.gabarx.com/2024/04/29/grx-917-is-a-potent-inhibitor-of-the-nlrp3-il-1-beta-inflammation-pathway/feed/ 0 2664 Precision qEEG Biomarker Demonstrates Anxiolytic Efficacy in Phase 1 GRX-917 and Phase 1 Etifoxine https://www.gabarx.com/2023/10/29/precision-qeeg-biomarker-demonstrates-anxiolytic-efficacy-in-phase-1-grx-917-and-phase-1-etifoxine/ https://www.gabarx.com/2023/10/29/precision-qeeg-biomarker-demonstrates-anxiolytic-efficacy-in-phase-1-grx-917-and-phase-1-etifoxine/#respond Sun, 29 Oct 2023 22:39:09 +0000 https://gabarx.com/?p=2668

qEEG biomarkers demonstrated anxiolytic efficacy in both Phase 1 of GRX-917 and Phase 1 of etifoxine.

  • qEEG Beta power increase
    • Rapid-onset, sustained activity
    • Time-dependent
    • Exposure-dependent
  • Increased qEEG Beta Power PD marker confirms
    • GABAA receptor target engagement
    • Anxiolytic efficacy biomarker

For questions contact:
Richard G. Farrell
Chief Financial Officer

Follow us on LinkedIn

We post current progress and developments on our GABA Therapeutics’ LinkedIn page. Click here to follow us LinkedIn.

GRX-917 qEEG Poster

]]> https://www.gabarx.com/2023/10/29/precision-qeeg-biomarker-demonstrates-anxiolytic-efficacy-in-phase-1-grx-917-and-phase-1-etifoxine/feed/ 0 2668